ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fluciclovine F-18

Also written as “18F fluciclovine”, “fluciclovine (18F)” and “18F-fluciclovine PET CT”.

Its studies are mostly in Prostatic Neoplasms · Brain Neoplasms, led by 2 companies.

Drug pageFluciclovine F-18: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 22, 20265 company-led studies, 1 open or runningNext primary completion: Dec 31, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bracco41 open or runningphase 4since Apr 22, 2026Jan 15, 2016Dec 31, 2027phase 4 · NCT07569926
GE Healthcareits history only10 open or runningphase 2since Aug 5, 2010Aug 5, 2010none ahead

Also a collaborator on its studies: Precision For Medicine, IND 2 Results and Syne Qua Non.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bracco only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 15, 2016First study: phase 3 study in Prostatic NeoplasmsFirst studyNCT02680041 · 221 enrolled · United States
  2. May 27, 2020Phase 2 study in Brain NeoplasmsNCT04410367 · 23 enrolled · United States
  3. May 27, 2020Phase 3 study in Brain NeoplasmsNCT04410133 · 151 enrolled · United States
  4. Apr 22, 2026Phase 4 study in Prostatic NeoplasmsNCT07569926 · 142 planned · United States

Ahead

  1. Dec 31, 2027Primary completion: phase 4 study in Prostatic NeoplasmsNCT07569926

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 Bracco leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07569926Prostatic Neoplasms · United States4RecruitingDec 31, 2027142
NCT04410367Brain Neoplasms · United States2CompletedDec 31, 202123
NCT04410133Brain Neoplasms · United States3CompletedJun 5, 2023151
NCT02680041Prostatic Neoplasms · United States3CompletedNov 1, 2017221

How it is read

Names in the registry

  • “18F fluciclovine”, 2 entries
  • “fluciclovine (18F)”, 1 entry
  • “18F-fluciclovine PET CT”, 1 entry
  • “GE-148 (18F)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.